Pharmaceutical IPR and Regulatory Affairs

Development of a new pharmaceutical product requires at least 15 years because of changes in the regulatory. Regulatory Affairs Department acts as the interface between the pharmaceutical company and the regulatory agencies across the world. Regulatory authorities act a vital role for approval of generics. Regulatory Affairs contributes essentially to the overall success of drug development, both at early pre-marketing stages and at all times post-marketing. Regulatory Affairs professionals can play a key role in guiding drug development strategy in an increasingly global environment. North America and Europe contribute about 57.0% of global pharmaceutical sales. The global regulatory affairs outsourcing market size was valued at USD 4.53 billion in 2016 and is expected to grow at a CAGR of 11.9% over the forecast period.

    Related Conference of Pharmaceutical IPR and Regulatory Affairs

    April 04-05, 2024

    17th European Biosimilars Congress

    Madrid, Spain
    April 11-12, 2024

    5th Annual Congress on Antibiotics and Bacterial Infections

    Amsterdam, Netherlands
    May 09-10, 2024

    4th Global Summit on Pharmaceutical Research

    Barcelona, Spain
    May 16-17, 2024

    18th World Drug Delivery Summit

    Rome, Italy
    May 30-31, 2024

    9th Pharmaceutical Chemistry Conference

    Paris, France
    September 11-12, 2024

    9th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    September 25-26, 2024

    4th World Congress on Rare Diseases & Orphan Drugs

    Paris, France
    November 28-29, 2024

    39th World Congress on Pharmacology and Therapeutics

    Paris, France
    December 05-06, 2024

    17th World Drug Delivery Summit

    Dubai, UAE

    Pharmaceutical IPR and Regulatory Affairs Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in